Claims for Patent: 8,486,446

Summary for Patent: 8,486,446

Title:	Oral antimicrobial pharmaceutical compositions
Abstract:	The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.
Inventor(s):	Ajani; Mauro (Milan, IT), Bozzella; Roberta (Milan, IT), Celasco; Giuseppe (Genoa, IT), Villa; Roberto (Lecco, IT)
Assignee:	Cosmo Technologies Ltd. (Dublin, IE)
Application Number:	11/571,044
Patent Claims:	1. Oral pharmaceutical composition providing controlled release or delayed release of rifamycin SV as an active ingredient or both controlled release and delayed release thereof, said composition containing rifamycin SV in association with one or more pharmacologically acceptable excipients(s), wherein the controlled and/or delayed release is given by a multi-matrix structure comprising: a) an amphiphilic matrix in which the active ingredient is incorporated; b) a lipophilic matrix which is formed by a substance having a melting point of less than 90.degree. C. and in which a) is dispersed; and c) a hydrophilic matrix, wherein release of the active ingredient takes place solely in the colon. 2. Pharmaceutical composition according to claim 1, wherein the rifamycin SV is contained in an amount of from 10 to 90% by weight. 3. Pharmaceutical composition according to claim 1, wherein the rifamycin SV is contained in an amount of from 20 to 60% by weight. 4. Pharmaceutical composition according to claim 1, wherein the amphiphilic matrix is selected from lecithin, polyoxyethylenated sorbitan monooleate, sodium lauryl sulphate, sodium dioctyl sulphosuccinate and/or ethylene and/or propylene block copolymers. 5. Pharmaceutical composition according to claim 1, wherein the lipophilic matrix is selected from stearic acid, beeswax, carnauba wax, palmitic acid and/or palmitostearate esters. 6. Pharmaceutical composition according to claim 1, wherein the hydrophilic matrix is selected from hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, polyvinyl alcohol, vinyl polymers, alginic acid and its salts and/or polysaccharide polymers. 7. Pharmaceutical composition according to claim 1, comprising a gastro-protective coating. 8. Pharmaceutical composition according to claim 7, wherein the gastro-protective coating is selected from acrylic and methacrylic acid esters and/or cellulose acetate phthalate. 9. Pharmaceutical composition according to claim 1, for the treatment of pathologies of the colon. 10. Pharmaceutical composition according to claim 1, for the treatment of infectious colitis, bacillary dysentery, pseudomembranous colitis, travellers' diarrhoea, diverticular disease and/or diverticulitis. 11. Pharmaceutical composition according to claim 1, for the treatment of infections of the colon. 12. Oral pharmaceutical composition containing rifamycin SV as an active ingredient and providing controlled release or delayed release of or both controlled release and delayed release the active ingredient, said composition containing the active ingredient in association with one or more pharmacologically acceptable excipients(s), wherein the release profile of the composition is achieved by a multi-matrix structure comprising: a) an amphiphilic matrix in which the active ingredient is incorporated; b) a lipophilic matrix which is formed by a substance having a melting point of less than 90.degree. C. and in which a) is dispersed; and c) a hydrophilic matrix, wherein in an enteric buffer at pH 7.2 less than about 30% of the active ingredient is released after lapse of one hour of residence of said composition and more than about 80% of the active ingredient is released after lapse of eight hours of residence of said composition in said buffer, and wherein release of the active ingredient takes place solely in the colon. 13. Pharmaceutical composition according to claim 10 for the treatment of travellers' diarrhea and diverticulitis. 14. Pharmaceutical composition according to claim 10 for the treatment of travellers' diarrhea. 15. Pharmaceutical composition according to claim 10 for the treatment of diverticulitis.